Business
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
ROCKVILLE, Md., May 2, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT)
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., May 2, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles, California from May 16 through 20, 2023. The presentations highlight the Company's end-to-end capabilities across clinical development and research and early development.\nThe presentations will be presented as follows:\nOral Presentations:\nAbstract Title: AUF1 Gene Therapy for Duchenne Muscular Dystrophy Increases Durable Endogenous Utrophin Expression, Muscle Regeneration and Muscle Function Performance in Pre-clinical Animal Studies (abstract #135)Presenter: Dounia Abbadi, Postdoctoral Fellow, NYU Langone Medical CenterSession: Gene Tx Approaches for Muscle & Skeletal DiseasesDate/Time: Thursday, May 18, 2023, 2:38-2:55 p.m. PST\nAbstract Title: Mechanistic Evaluation of Liver-specific Transgene Repression from AAV Vectors in Non-Human Primates and Minipigs (abstract #249)Presenter: Zhuo Wang, Ph.D., Scientist II, Research & Early Development at REGENXBIOSession: AAV Vector Genome Biology & Engineering IIDate/Time: Friday, May 19 3:45-4:00 p.m. PST\nPoster Presentations:\nAbstract Title: RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study (abstract #807)Presenter: Paul Harmatz, M.D., Professor in Residence at University of California, San FranciscoSession: Wednesday Poster SessionDate/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST\nAbstract Title: In Silico Prediction and In Vivo Testing of Promoters Targeting GABAergic Inhibitory Neurons (abstract #385)Presenter: Robert Duba-Kiss, Ph.D. Candidate, Pharmacology/Neuroscience at University of Toronto University of TorontoSession: Wednesday Poster SessionDate/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST\nAbstract Title: Development of AAV-Expressed C5 Inhibitor to Locally Suppress Complement Pathway Activation in the Eye as a Potential Treatment for Dry Age-related Macular Degeneration (abstract #364)Presenter: Wei-Hua Lee, Ph.D., Senior Scientist, Research & Early Development at REGENXBIOSession: Wednesday Poster SessionDate/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST\nAbstract Title: Addition of a ...